Miragen Therapeutics 2017 Cowen Health Care Conference

Miragen Therapeutics presented its RNA-targeted therapeutic pipeline focused on correcting microRNA dysregulation to treat disease. The clinical-stage biopharmaceutical company discussed initial 2016 clinical data from MRG-106 in hematological malignancies and MRG-201 in cutaneous fibrosis, following a progressive de-risking strategy in early trials.